NSE · VENUSREM · Pharmaceuticals
Venus Remedies Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹219 Cr with net profit ₹29 Cr — a 13.24% net margin, versus 14.28% the period before.
Shareholding
As of 2026-09-30
- Promoter41.76%
- Public54.36%
- FII3.14%
- DII0.74%
22,968 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 4.73× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 4. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #13 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,75,920 Cr | 81.03 | 9.53 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹48,848 Cr | 42.63 | 4.72 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹41,906 Cr | 36.93 | 9.24 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹24,989 Cr | 86.71 | 19.46 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹17,881 Cr | 26.88 | 5.31 | 17.88% | 29.09% |
| Shilpa Medicare Ltd. | ₹17,694 Cr | 62.22 | 6.82 | 9.39% | 17.67% |
| Eris Lifesciences Limited | ₹16,626 Cr | 22.21 | 4.01 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹13,599 Cr | 26.32 | 4.5 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹6,801 Cr | 49.4 | 5.74 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,038 Cr | 47.78 | 6.46 | 12.36% | 18.59% |
| Venus Remedies Limited(this company) | ₹1,856 Cr | 15.98 | 2.62 | 17.27% | 14.54% |
AI analysis
AI-generated · google/gemini-2.5-flashVenus Remedies Limited has a market capitalization of Rs 2373 Cr. The company reported revenue of Rs 668.84 Cr and an EPS of 39.32. The debt-to-equity ratio is 0.04.
Positives
- +The company has a low debt-to-equity ratio of 0.04.
- +Promoter pledge is 0% as of June 2026, down from 100% in June 2018.
- +The promoter shareholding has increased from 37.5142% in June 2018 to 41.7596% in June 2026.
Negatives
- −The company's Return on Equity (ROE) is 8.1% and Return on Capital Employed (ROCE) is 11.75%.
- −There are no dividend yield figures available.
- −The company is under surveillance categorized as 'LT-ASM · ASM 4'.
Financial Performance
Venus Remedies Limited reported annual revenue of Rs 178.8 Cr in June 2026, building on previous quarters of Rs 259.01 Cr in March 2026, Rs 179.95 Cr in December 2025, and Rs 192.65 Cr in September 2025. Net profit was Rs 25.53 Cr in June 2026, following Rs 43.45 Cr in March 2026, Rs 24.92 Cr in December 2025, and Rs 19.24 Cr in September 2025.
Profitability & Returns
The company's Return on Equity (ROE) stands at 8.1% and Return on Capital Employed (ROCE) is 11.75%. The earnings per share (EPS) is reported at 39.32. The PE ratio for the company is 7.62.
Balance Sheet
Venus Remedies Limited maintains a low debt-to-equity ratio of 0.04. The book value per share is 441.01. The company has a market capitalization of Rs 2373 Cr.
Ownership & Pledges
As of June 2026, promoter holding is 41.7596%, while public shareholding is 54.4335%. There are no promoter shares pledged currently.
Regulatory & Surveillance
Venus Remedies Limited is subject to surveillance measures under the 'LT-ASM' framework (ASM 4), indicating heightened monitoring by regulatory authorities.
Data as of — price: 2026-10-28 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.